Published in BJU Int on July 28, 2006
Contemporary management of low-risk bladder cancer. Nat Rev Urol (2011) 0.93
The 1973 WHO Classification is more suitable than the 2004 WHO Classification for predicting prognosis in non-muscle-invasive bladder cancer. PLoS One (2012) 0.84
Reproductibilité des classifications OMS 1973 et OMS 2004 des tumeurs urothéliales papillaires de la vessie. Can Urol Assoc J (2011) 0.75
Micro-RNA profiling in kidney and bladder cancers. Urol Oncol (2007) 4.35
Anesthetic technique for radical prostatectomy surgery affects cancer recurrence: a retrospective analysis. Anesthesiology (2008) 2.75
Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology. BJU Int (2010) 2.59
Cystic nephroma and mixed epithelial and stromal tumour of the kidney: opposite ends of the spectrum of the same entity? Eur Urol (2007) 2.33
Immunoglobulin G4-related disease in genitourinary organs: an emerging fibroinflammatory entity often misdiagnosed preoperatively as cancer. Eur Urol (2012) 2.18
Side-effects of treatments for locally advanced prostate cancer. BJU Int (2006) 2.03
Words of wisdom: re: multilocular cystic renal cell carcinoma with focus on clinical and pathobiological aspects. Eur Urol (2013) 2.00
Small cell carcinoma of the urinary bladder: a clinicopathologic analysis of 64 patients. Cancer (2004) 1.85
Prognostic and therapeutic impact of the histopathologic definition of parenchymal epithelial renal tumors. Eur Urol (2010) 1.79
Interobserver reproducibility in the diagnosis of invasive micropapillary carcinoma of the urinary tract among urologic pathologists. Am J Surg Pathol (2010) 1.73
The 2004 WHO classification of bladder tumors: a summary and commentary. Int J Surg Pathol (2005) 1.73
Neuroendocrine tumours of the urinary system and male genital organs: clinical significance. BJU Int (2009) 1.71
2005 update on pathology of prostate biopsies with cancer. Eur Urol (2006) 1.66
Benign prostatic hyperplasia: counting the cost of its management. BJU Int (2010) 1.64
Molecular genetic evidence for the independent origin of multifocal papillary tumors in patients with papillary renal cell carcinomas. Clin Cancer Res (2005) 1.63
The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations. J Urol (2006) 1.63
Optimising repeat prostate biopsy decisions and procedures. BJU Int (2011) 1.62
Evidence for common clonal origin of multifocal lung cancers. J Natl Cancer Inst (2009) 1.59
ERG-TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin. Mod Pathol (2011) 1.59
Heat shock proteins: their role in urological tumors. J Urol (2003) 1.56
Indicators for research performance evaluation: an overview. BJU Int (2012) 1.56
A catalyst for change: the European cancer Patient's Bill of Rights. Oncologist (2014) 1.55
The relationship between the extent of surgical margin positivity and prostate specific antigen recurrence in radical prostatectomy specimens. Hum Pathol (2007) 1.53
A meta-analysis of trials of transurethral needle ablation for treating symptomatic benign prostatic hyperplasia. BJU Int (2004) 1.53
Soft tissue tumors of the urinary bladder, Part I: myofibroblastic proliferations, benign neoplasms, and tumors of uncertain malignant potential. Hum Pathol (2007) 1.52
Original Gleason system versus 2005 ISUP modified Gleason system: the importance of indicating which system is used in the patient's pathology and clinical reports. Eur Urol (2010) 1.51
Molecular pathology of lung cancer: key to personalized medicine. Mod Pathol (2012) 1.50
Evidence that inhibition of tubular cell apoptosis protects against renal damage and development of fibrosis following ureteric obstruction. Am J Physiol Renal Physiol (2006) 1.44
Perspectives on treatment of metastatic castration-resistant prostate cancer. Oncologist (2013) 1.42
Radical prostatectomy vs watchful waiting. BJU Int (2005) 1.41
Can lifestyle modification lower the risk of prostate cancer? BJU Int (2010) 1.40
Current prospects for the chemoprevention of prostate cancer. BJU Int (2010) 1.39
Are the National Institute for Health and Clinical Excellence guidelines that promulgate active surveillance for low-risk prostate cancer justified by the available evidence? BJU Int (2008) 1.39
Search for residual prostate cancer on pT0 radical prostatectomy after positive biopsy. Virchows Arch (2007) 1.39
Laparoscopic nephroureterectomy for upper urinary tract transitional cell carcinoma: is it better than open surgery? Eur Urol (2004) 1.39
Paraneoplastic syndromes in patients with urological malignancies. Urol Int (2009) 1.36
Rare and unusual histological variants of prostatic carcinoma: clinical significance. BJU Int (2008) 1.36
Heat shock proteins HSP27, HSP60, HSP70, and HSP90: expression in bladder carcinoma. Cancer (2003) 1.35
Background for the proposal of SIOG guidelines for the management of prostate cancer in senior adults. Crit Rev Oncol Hematol (2010) 1.34
Bladder cancer: translating molecular genetic insights into clinical practice. Hum Pathol (2010) 1.33
TGF-beta1-induced EMT can occur independently of its proapoptotic effects and is aided by EGF receptor activation. Am J Physiol Renal Physiol (2005) 1.33
Characterisation and manipulation of docetaxel resistant prostate cancer cell lines. Mol Cancer (2011) 1.32
The plasmacytoid carcinoma of the bladder--rare variant of aggressive urothelial carcinoma. Int J Cancer (2010) 1.29
Inflammatory myofibroblastic tumors of the kidney: a clinicopathologic and immunohistochemical study of 12 cases. Am J Surg Pathol (2003) 1.28
Adult primary paratesticular mesenchymal tumors with emphasis on a case presentation and discussion of spermatic cord leiomyosarcoma. Diagn Pathol (2014) 1.26
Molecular and cytogenetic insights into the pathogenesis, classification, differential diagnosis, and prognosis of renal epithelial neoplasms. Hum Pathol (2009) 1.24
Staging and reporting of urothelial carcinoma of the urinary bladder. Mod Pathol (2009) 1.24
Inflammatory myofibroblastic tumors of the genitourinary tract--single entity or continuum? J Urol (2008) 1.22
Thyroid transcription factor 1 expression in small cell carcinoma of the urinary bladder: an immunohistochemical profile of 44 cases. Hum Pathol (2005) 1.21
Core fucosylation and alpha2-3 sialylation in serum N-glycome is significantly increased in prostate cancer comparing to benign prostate hyperplasia. Glycobiology (2010) 1.20
Staging of prostate cancer. Histopathology (2012) 1.19
Multilocular cystic renal cell carcinoma is a subtype of clear cell renal cell carcinoma. Mod Pathol (2010) 1.19
Molecular evidence supporting field effect in urothelial carcinogenesis. Clin Cancer Res (2005) 1.19
Ureteral endometriosis: clinicopathological and immunohistochemical study of 7 cases. Hum Pathol (2008) 1.19
Molecular genetic evidence for a common clonal origin of urinary bladder small cell carcinoma and coexisting urothelial carcinoma. Am J Pathol (2005) 1.19
Expression of S100 protein family members in the pathogenesis of bladder tumors. Anticancer Res (2007) 1.18
Role of targeted therapy in the treatment of advanced prostate cancer. BJU Int (2010) 1.16
Prostate epithelial cell differentiation and its relevance to the understanding of prostate cancer therapies. Clin Sci (Lond) (2005) 1.16
Immunosuppressive therapy for idiopathic retroperitoneal fibrosis: a retrospective analysis of 26 cases. Am J Med (2004) 1.15
Handling and staging of renal cell carcinoma: the International Society of Urological Pathology Consensus (ISUP) conference recommendations. Am J Surg Pathol (2013) 1.15
Inhibitors of apoptosis proteins in prostate cancer cell lines. Prostate (2002) 1.15
Germ cell origin of testicular carcinoid tumors. Clin Cancer Res (2008) 1.15
Amplifications of EGFR gene and protein expression of EGFR, Her-2/neu, c-kit, and androgen receptor in phyllodes tumor of the prostate. Mod Pathol (2006) 1.15
A working group classification of focal prostate atrophy lesions. Am J Surg Pathol (2006) 1.13
PED mediates AKT-dependent chemoresistance in human breast cancer cells. Cancer Res (2005) 1.12
Role of immunohistochemistry in diagnosing renal neoplasms: when is it really useful? Arch Pathol Lab Med (2012) 1.12
Lymphoepithelioma-like carcinoma of the urinary bladder: clinicopathologic, immunohistochemical, and molecular features. Am J Surg Pathol (2011) 1.11
Sarcomatoid carcinoma of the urinary bladder: the final common pathway of urothelial carcinoma dedifferentiation. Am J Surg Pathol (2011) 1.11
Resveratrol sensitizes androgen independent prostate cancer cells to death-receptor mediated apoptosis through multiple mechanisms. Prostate (2007) 1.10
Electronic learning can facilitate student performance in undergraduate surgical education: a prospective observational study. BMC Med Educ (2005) 1.09
Solitary fibrous tumour of the prostate identified on needle biopsy. Eur Urol (2009) 1.09
Telomere shortening and chromosomal abnormalities in intestinal metaplasia of the urinary bladder. Clin Cancer Res (2007) 1.09
Standardization of Gleason grading among 337 European pathologists. Histopathology (2013) 1.09
Histogenesis of clear cell adenocarcinoma in the urinary tract: evidence of urothelial origin. Clin Cancer Res (2008) 1.08
Epidermal growth factor receptor protein expression and gene amplification in small cell carcinoma of the urinary bladder. Clin Cancer Res (2007) 1.08
Natural history of urothelial inverted papilloma. Cancer (2006) 1.08
Biomarker research in prostate cancer--towards utility, not futility. Nat Rev Urol (2011) 1.07
Soft tissue tumors of the urinary bladder Part II: malignant neoplasms. Hum Pathol (2007) 1.07
Chromatin phenotype karyometry can predict recurrence in papillary urothelial neoplasms of low malignant potential. Cell Oncol (2007) 1.06
Epidemiology of testicular cancer. BJU Int (2009) 1.06
Sarcomatoid carcinoma of the upper urinary tract: clinical outcome and molecular characterization. Hum Pathol (2008) 1.05
Divergent pathway of intestinal metaplasia and cystitis glandularis of the urinary bladder. Mod Pathol (2006) 1.05
Urothelial carcinoma with an inverted growth pattern can be distinguished from inverted papilloma by fluorescence in situ hybridization, immunohistochemistry, and morphologic analysis. Am J Surg Pathol (2007) 1.05
TP53 mutational analysis supports monoclonal origin of biphasic sarcomatoid urothelial carcinoma (carcinosarcoma) of the urinary bladder. Mod Pathol (2008) 1.05
Mechanisms of disease: high-grade prostatic intraepithelial neoplasia and other proposed preneoplastic lesions in the prostate. Nat Clin Pract Urol (2007) 1.05
Spontaneous production of monocyte chemoattractant protein-1 and interleukin-8 by the human lumbar intervertebral disc. Spine (Phila Pa 1976) (2002) 1.04
BMI and the risk of renal cell carcinoma. Curr Opin Urol (2011) 1.03
FEZ1/LZTS1 is down-regulated in high-grade bladder cancer, and its restoration suppresses tumorigenicity in transitional cell carcinoma cells. Am J Pathol (2002) 1.03
Expression of KISS1 and MMP-9 in non-small cell lung cancer and their relations to metastasis and survival. Anticancer Res (2010) 1.03
Sexual counseling improved erectile rehabilitation after non-nerve-sparing radical retropubic prostatectomy or cystectomy--results of a randomized prospective study. J Sex Med (2006) 1.02
Is incidentally detected prostate cancer in patients undergoing radical cystoprostatectomy clinically significant? Am J Clin Pathol (2009) 1.02
Social, economic, and health utility considerations in the treatment of overactive bladder. Open Access J Urol (2010) 1.00
Secondary neoplasms of the urinary system and male genital organs. BJU Int (2009) 1.00
Laser capture microdissection in the genomic and proteomic era: targeting the genetic basis of cancer. Int J Clin Exp Pathol (2008) 1.00
Sex-specific alterations in neutrophil apoptosis: the role of estradiol and progesterone. Blood (2003) 1.00